a 192

A 192 is a biochemical.

MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC50 values of 30 nM and 16 nM, respectively. It exhibits greater selectivity for HDAC2/3 over other HDAC isomers and induces apoptosis in myeloid leukemic cells, indicating potential therapeutic use in leukemia and as an anti-stroke agent [1] [2].

AGH-192, an efficient agonist with compound-like properties, may serve as an ideal tool compound for studying 5-HT7 receptor functions. Furthermore, its observed analgesic effects in a murine neuropathic pain model indicate its potential as a pain-relieving medication.

Antitumor agent-192 (Compound 2f) is a β-carboline antitumor compound. It induces autophagy in HCT116 cells via the ATG5/ATG7 pathway. The IC50 of Antitumor agent-192 against human tumor cell lines is below 5 μM, and it significantly inhibits tumor growth and reduces tumor weight in xenograft mouse models of colorectal cancer.

Anticanceragent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinic and hERG receptors. It shows considerable stability in human and rat liver microsomes. Additionally, in addiction tests conducted on rats, Anticanceragent 192 enhances cognitive levels and reduces addiction severity.

Tyrosinase (192-200), a human mouse nonapeptide, is recognizable by cytolytic T cells (CTL) on the HLA-B44 molecule and is utilized in the research of melanoma-associated cancers [1].

YLT192 is an orally active and bioavailable VEGFR2 inhibitor. It also has potent antiangiogenic activity and antitumor efficacy.

LBX192( NVP-LBX192) is a liver-targeted glucokinase activator.

ML192 (CID1434953) is a selective GPR55 ligand antagonist. ML192 is an inhibitor that inhibits β-arrestin transport, ERK1/2 phosphorylation, and PKCβII translocation.

TAT-PAK18 R192A is an inactive Tat-Pak peptide. It does not influence Rac1 translocation triggered by any tested proteins.

A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).

ent-Kaurane-16beta,19,20-triol is a natural product for research related to life sciences. The catalog number is TN3958 and the CAS number is 167898-32-0.

TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM), showing >70% inhibition of Syk and four other kinases [FLT3 (IC50: 10 nM), JAK2 (IC50: 4.8 nM), KDR (IC50: 600 nM), RET (IC50: 29 nM)] in a panel of 192 kinases.

5-HT1AR Agonist 2 (Compound 4f) is a potent agonist of the 5-HT1A receptor with a Ki value of 10.0 nM. It also binds to SERT, D2, and 5-HT6 receptors with Ki values of 2.8 nM, 23 nM, and 192 nM, respectively. Furthermore, this compound demonstrates stability in microsomes and induces hypothermia in mice.

PRMT6-IN-3 is a selective PRMT6 inhibitor with an IC50 value of 192 nM.PRMT6-IN-3 has anticancer activity and induces apoptosis in cancer cells.

Mambalgin 1 TFA, a selective inhibitor of ASIC1a (with IC50 values of 192 nM for human ASIC1a and 72 nM for the ASIC1a/1b dimer), preferentially binds to the channel in its closed/inactive state. It demonstrates selectivity for ASIC1a over a range of other channels, including ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2, and Kv1.2. In vivo, Mambalgin 1 TFA effectively prolongs the latency of the withdrawal response in mouse tail-flick and paw-flick tests.

SHP2-IN-17 (compound 192) is a potent SHP2 inhibitor with an IC50 of 2 nM, showing potential for glioblastoma research [1].